1. Veronesi B, Oortgiesen M. The TRPV1 receptor: target of toxicants and therapeutics. Toxicol Sci. 2006; 89:1–3.
Article
2. Chou MZ, Mtui T, Gao YD, Kohler M, Middleton RE. Resiniferatoxin binds to the capsaicin receptor (TRPV1) near the extracellular side of the S4 transmembrane domain. Biochemistry. 2004; 43:2501–2511.
Article
3. Salazar H, Jara-Oseguera A, Hernández-García E, Llorente I, Arias-Olguín II, Soriano-García M, et al. Structural determinants of gating in the TRPV1 channel. Nat Struct Mol Biol. 2009; 16:704–710.
Article
4. Everaerts W, Sepúlveda MR, Gevaert T, Roskams T, Nilius B, De Ridder D. Where is TRPV1 expressed in the bladder, do we see the real channel? Naunyn Schmiedebergs Arch Pharmacol. 2009; 379:421–425.
Article
5. Li J, Wang DH. Increased GFR and renal excretory function by activation of TRPV1 in the isolated perfused kidney. Pharmacol Res. 2008; 57:239–246.
Article
6. Kauer JA, Gibson HE. Hot flash: TRPV channels in the brain. Trends Neurosci. 2009; 32:215–224.
Article
7. Lin YS, Lin RL, Bien MY, Ho CY, Kou YR. Sensitization of capsaicin-sensitive lung vagal afferents by anandamide in rats: role of transient receptor potential vanilloid 1 receptors. J Appl Physiol (1985). 2009; 106:1142–1152.
Article
8. Caterina MJ. Transient receptor potential ion channels as participants in thermosensation and thermoregulation. Am J Physiol Regul Integr Comp Physiol. 2007; 292:R64–R76.
Article
9. Nilius B. TRP channels in disease. Biochim Biophys Acta. 2007; 1772:805–812.
Article
10. Marincsák R, Tóth BI, Czifra G, Márton I, Rédl P, Tar I, et al. Increased expression of TRPV1 in squamous cell carcinoma of the human tongue. Oral Dis. 2009; 15:328–335.
Article
11. Czifra G, Varga A, Nyeste K, Marincsák R, Tóth BI, Kovács I, et al. Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J Cancer Res Clin Oncol. 2009; 135:507–514.
Article
12. Santoni G, Caprodossi S, Farfariello V, Liberati S, Gismondi A, Amantini C. Antioncogenic effects of transient receptor potential vanilloid 1 in the progression of transitional urothelial cancer of human bladder. ISRN Urol. 2012; 2012:458238.
Article
13. Zhang L, Barritt GJ. TRPM8 in prostate cancer cells: a potential diagnostic and prognostic marker with a secretory function? Endocr Relat Cancer. 2006; 13:27–38.
Article
14. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 2012; 36:237–248.
Article
15. Scatchard G. The attractions of proteins for small molecules and ions. Ann N Y Acad Sci. 1949; 51:660–672.
Article
16. Tóth A, Blumberg PM, Chen Z, Kozikowski AP. Design of a high-affinity competitive antagonist of the vanilloid receptor selective for the calcium entry-linked receptor population. Mol Pharmacol. 2004; 65:282–291.
Article
17. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22:3099–3108.
18. Ho WY, Yeap SK, Ho CL, Rahim RA, Alitheen NB. Development of multicellular tumor spheroid (MCTS) culture from breast cancer cell and a high throughput screening method using the MTT assay. PLoS One. 2012; 7:e44640.
Article
19. Sanchez MG, Sanchez AM, Collado B, Malagarie-Cazenave S, Olea N, Carmena MJ, et al. Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. Eur J Pharmacol. 2005; 515:20–27.
Article
20. Bodó E, Kovács I, Telek A, Varga A, Paus R, Kovács L, et al. Vanilloid receptor-1 (VR1) is widely expressed on various epithelial and mesenchymal cell types of human skin. J Invest Dermatol. 2004; 123:410–413.
Article
21. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006; 318:1375–1387.
Article
22. Dhennin-Duthille I, Gautier M, Faouzi M, Guilbert A, Brevet M, Vaudry D, et al. High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters. Cell Physiol Biochem. 2011; 28:813–822.
Article
23. Rigoni M, Trevisani M, Gazzieri D, Nadaletto R, Tognetto M, Creminon C, et al. Neurogenic responses mediated by vanilloid receptor-1 (TRPV1) are blocked by the high affinity antagonist, iodo-resiniferatoxin. Br J Pharmacol. 2003; 138:977–985.
Article
24. Rossi T, Castelli M, Zandomeneghi G, Ruberto A, Benassi L, Magnoni C, et al. Selectivity of action of glycyrrhizin derivatives on the growth of MCF-7 and HEP-2 cells. Anticancer Res. 2003; 23(5A):3813–3818.
25. Contassot E, Tenan M, Schnüriger V, Pelte MF, Dietrich PY. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol Oncol. 2004; 93:182–188.
Article
26. Kalogris C, Caprodossi S, Amantini C, Lambertucci F, Nabissi M, Morelli MB, et al. Expression of transient receptor potential vanilloid-1 (TRPV1) in urothelial cancers of human bladder: relation to clinicopathological and molecular parameters. Histopathology. 2010; 57:744–752.
Article
27. Sanz-Salvador L, Andrés-Borderia A, Ferrer-Montiel A, Planells-Cases R. Agonist- and Ca2+-dependent desensitization of TRPV1 channel targets the receptor to lysosomes for degradation. J Biol Chem. 2012; 287:19462–19471.
Article
28. Menéndez L, Juárez L, García E, García-Suárez O, Hidalgo A, Baamonde A. Analgesic effects of capsazepine and resiniferatoxin on bone cancer pain in mice. Neurosci Lett. 2006; 393:70–73.
Article
29. Santoni G, Farfariello V. TRP channels and cancer: new targets for diagnosis and chemotherapy. Endocr Metab Immune Disord Drug Targets. 2011; 11:54–67.
Article
30. Sung B, Prasad S, Ravindran J, Yadav VR, Aggarwal BB. Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors. Free Radic Biol Med. 2012; 53:1977–1987.
Article